# Contraceptive Efficacy and Safety of NOMAC-E2 Combined Oral Contraceptive

> **NCT05264506** · PHASE3 · TERMINATED · sponsor: **Organon and Co** · enrollment: 3055 (actual)

## Conditions studied

- Contraception

## Interventions

- **DRUG:** NOMAC-E2 COC

## Key facts

- **NCT ID:** NCT05264506
- **Lead sponsor:** Organon and Co
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-02-17
- **Primary completion:** 2024-01-12
- **Final completion:** 2024-01-26
- **Target enrollment:** 3055 (ACTUAL)
- **Why stopped:** Sponsor decision to stop the study early and complete all required study close-out activities. This decision was made for business reasons unrelated to safety. None of the pre-specified efficacy endpoints were analyzed.
- **Last updated:** 2025-11-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05264506

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05264506, "Contraceptive Efficacy and Safety of NOMAC-E2 Combined Oral Contraceptive". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05264506. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*